Allergenis, a Pennsylvania-based provider of advanced food allergy testing solutions, is actively seeking funding to support its innovative technology that accurately determines allergic status and assesses tolerance levels. With the food allergy epidemic affecting 32 million Americans, including one in 13 children, Allergenis aims to alleviate the mental, emotional, and financial burdens faced by individuals, parents, and caregivers.
Existing food allergy testing methods fail to provide a comprehensive understanding of an individual's allergy spectrum, often leading to ambiguous and inaccurate results. The current blood-test options in the market to diagnose peanut allergies exhibit a false-positive rate as high as 60%. On the other hand, the gold standard tool, an oral food challenge (OFC), is not only costly and time-consuming but also anxiety-inducing due to the potential risk of severe reactions, and is often avoided as a result.
Allergenis is transforming the food allergy diagnostic landscape by offering patients more testing options and enhanced clarity regarding their food allergies. Through cutting-edge systems biology and data analytics, Allergenis analyzes blood samples to determine an individual's allergic status accurately and thoroughly. This breakthrough technology enables individuals to make informed decisions about their food choices, leading to a better quality of life.
"Our mission is to empower individuals living with food allergies by providing them with comprehensive testing options and accurate information about their allergies. By utilizing our innovative blood test, individuals can confidently consume food without the fear of severe allergic reactions,” says Jim Garner, the CEO of Allergenis.
Allergenis currently offers a state of the art blood test to diagnose peanut allergies and are in the process of finalizing their next product that will improve the diagnosis of cow's milk allergies. The Allergenis testing process involves analyzing a blood sample to determine the likelihood of an allergic reaction to a specific food. The results provide a probability percentage, indicating the chances of reacting to a particular allergen. This information allows individuals to discuss their threshold with a healthcare provider to help make informed decisions about their food choices. For instance, if the test reveals a low probability of an allergic reaction to peanuts, individuals can consume the food in front of a healthcare provider without fear of severe consequences.
Conversely, if the test indicates a higher probability of an allergic reaction, Allergenis provides specific information about the level of tolerance. For example, if a person is found to be likely allergic to peanuts, the test might suggest they are unlikely to react unless they consume a certain threshold. This valuable information allows individuals confidently navigate social situations involving food, such as birthday parties, where accidental exposure to allergens may occur.
“People don't think about the true ramifications that allergies cause. It’s not only the individual who is affected but those who surround them. Whether that be a parent who has to put limitations on their child's upbringing, a business who has to find cover because a member of staff is frequently absent due to caring for a child, or the healthcare industry that is unnecessarily burdened. People simply do not know whether they have an allergy or not, and when they are allergic how much could be safe to consume or how much needs to be avoided.” says Jim Garner.
Furthermore, Allergenis is actively collaborating with therapeutic developers worldwide to establish its blood test as a surrogate for oral food challenges in clinical trials. Traditionally, clinical trials for food allergies required individuals to consume the allergen and experience a reaction to qualify for participation. By validating their blood test as a reliable alternative, Allergenis aims to facilitate more clinical trials, leading to the development of a diverse range of therapies for food allergies.
"We are working closely with renowned research centers such as Mount Sinai and Stanford in the US, and the King's College, and the Imperial College of London in the UK, as well as several academic institutions and researchers across Europe, the United States, Australia, and beyond. The enthusiastic response from global thought leaders reinforces the importance of our breakthroughs and motivates us to commercialize our products for the benefit of those living with food allergies", Jim Garner added.
To accomplish this vision, Allergenis is actively seeking growth capital to support the commercialization efforts and establish a sales force. The funding will enable Allergenis to bring its innovative food allergy testing technology to a wider audience, empowering individuals, and improving their quality of life.
Media contact:
Name: Jim Garner
Email: [email protected]
Disclaimer: Not an offer to buy or sell securities investment -There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax situation.
